Günlemez, A. 2022. Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. NEW ENGLAND JOURNAL OF MEDICINE , vol.386, no.3 , 892-894.

Günlemez, A., (2022). Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. NEW ENGLAND JOURNAL OF MEDICINE , vol.386, no.3, 892-894.

Günlemez, AYLA. "Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity," NEW ENGLAND JOURNAL OF MEDICINE , vol.386, no.3, 892-894, 2022

Günlemez, AYLA. "Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity." NEW ENGLAND JOURNAL OF MEDICINE , vol.386, no.3, pp.892-894, 2022

Günlemez, A. (2022) . "Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity." NEW ENGLAND JOURNAL OF MEDICINE , vol.386, no.3, pp.892-894.

@article{article, author={AYLA GÜNLEMEZ}, title={Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity}, journal={NEW ENGLAND JOURNAL OF MEDICINE}, year=2022, pages={892-894} }